Diabetic cardiomyopathy - a distinct disease?

Kaivan Khavandi, Ali Khavandi, Omar Asghar, Adam Greenstein, Sarah Withers, Anthony M. Heagerty, Rayaz Malik

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Diabetic individuals have a significantly increased likelihood of developing cardiovascular disease. Whilst part of this association is explained by the presence of concomitant risk factors, large epidemiological studies have consistently reported diabetes as a strong risk factor for the development of heart failure after adjusting for such covariates. This has resulted in the notion that there is a distinct cardiomyopathy specific to diabetes, termed 'diabetic cardiomyopathy'. The natural history is characterized by a latent subclinical period, during which there is evidence of diastolic dysfunction and left ventricular hypertrophy, before overt clinical deterioration and systolic failure ensue. These clinical findings have been supported by a growing body of experimental data which support the notion that diabetes inflicts a direct insult to the myocardium, with cellular, structural and functional changes manifest as the diabetic myocardial phenotype. Several of these mechanisms appear to work in unison, forming complicated reciprocal pathways of disease. Reactive oxygen species and alterations in intracellular calcium homeostasis appear to play significant roles in many of these mechanisms. Determining the hierarchy of this cascade of disease will allow identification of the pathological trigger most responsible for disease. Translational research in this field is currently hindered by a lack of clinical studies and intervention trials specifically in patients with diabetic cardiomyopathy. Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients.

Original languageEnglish
Pages (from-to)347-360
Number of pages14
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume23
Issue number3
DOIs
Publication statusPublished - Jun 2009
Externally publishedYes

Fingerprint

Diabetic Cardiomyopathies
Translational Medical Research
Left Ventricular Hypertrophy
Natural History
Cardiomyopathies
Epidemiologic Studies
Reactive Oxygen Species
Myocardium
Homeostasis
Cardiovascular Diseases
Heart Failure
Calcium
Morbidity
Phenotype
Drug Therapy
Mortality
Clinical Studies

Keywords

  • cardiomyocyte
  • cardiomyopathy
  • diabetes
  • heart failure

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Khavandi, K., Khavandi, A., Asghar, O., Greenstein, A., Withers, S., Heagerty, A. M., & Malik, R. (2009). Diabetic cardiomyopathy - a distinct disease? Best Practice and Research: Clinical Endocrinology and Metabolism, 23(3), 347-360. https://doi.org/10.1016/j.beem.2008.10.016

Diabetic cardiomyopathy - a distinct disease? / Khavandi, Kaivan; Khavandi, Ali; Asghar, Omar; Greenstein, Adam; Withers, Sarah; Heagerty, Anthony M.; Malik, Rayaz.

In: Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 23, No. 3, 06.2009, p. 347-360.

Research output: Contribution to journalReview article

Khavandi, K, Khavandi, A, Asghar, O, Greenstein, A, Withers, S, Heagerty, AM & Malik, R 2009, 'Diabetic cardiomyopathy - a distinct disease?', Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 23, no. 3, pp. 347-360. https://doi.org/10.1016/j.beem.2008.10.016
Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM et al. Diabetic cardiomyopathy - a distinct disease? Best Practice and Research: Clinical Endocrinology and Metabolism. 2009 Jun;23(3):347-360. https://doi.org/10.1016/j.beem.2008.10.016
Khavandi, Kaivan ; Khavandi, Ali ; Asghar, Omar ; Greenstein, Adam ; Withers, Sarah ; Heagerty, Anthony M. ; Malik, Rayaz. / Diabetic cardiomyopathy - a distinct disease?. In: Best Practice and Research: Clinical Endocrinology and Metabolism. 2009 ; Vol. 23, No. 3. pp. 347-360.
@article{b3c5e3e586024bcaa5f3ff8575912aed,
title = "Diabetic cardiomyopathy - a distinct disease?",
abstract = "Diabetic individuals have a significantly increased likelihood of developing cardiovascular disease. Whilst part of this association is explained by the presence of concomitant risk factors, large epidemiological studies have consistently reported diabetes as a strong risk factor for the development of heart failure after adjusting for such covariates. This has resulted in the notion that there is a distinct cardiomyopathy specific to diabetes, termed 'diabetic cardiomyopathy'. The natural history is characterized by a latent subclinical period, during which there is evidence of diastolic dysfunction and left ventricular hypertrophy, before overt clinical deterioration and systolic failure ensue. These clinical findings have been supported by a growing body of experimental data which support the notion that diabetes inflicts a direct insult to the myocardium, with cellular, structural and functional changes manifest as the diabetic myocardial phenotype. Several of these mechanisms appear to work in unison, forming complicated reciprocal pathways of disease. Reactive oxygen species and alterations in intracellular calcium homeostasis appear to play significant roles in many of these mechanisms. Determining the hierarchy of this cascade of disease will allow identification of the pathological trigger most responsible for disease. Translational research in this field is currently hindered by a lack of clinical studies and intervention trials specifically in patients with diabetic cardiomyopathy. Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients.",
keywords = "cardiomyocyte, cardiomyopathy, diabetes, heart failure",
author = "Kaivan Khavandi and Ali Khavandi and Omar Asghar and Adam Greenstein and Sarah Withers and Heagerty, {Anthony M.} and Rayaz Malik",
year = "2009",
month = "6",
doi = "10.1016/j.beem.2008.10.016",
language = "English",
volume = "23",
pages = "347--360",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Diabetic cardiomyopathy - a distinct disease?

AU - Khavandi, Kaivan

AU - Khavandi, Ali

AU - Asghar, Omar

AU - Greenstein, Adam

AU - Withers, Sarah

AU - Heagerty, Anthony M.

AU - Malik, Rayaz

PY - 2009/6

Y1 - 2009/6

N2 - Diabetic individuals have a significantly increased likelihood of developing cardiovascular disease. Whilst part of this association is explained by the presence of concomitant risk factors, large epidemiological studies have consistently reported diabetes as a strong risk factor for the development of heart failure after adjusting for such covariates. This has resulted in the notion that there is a distinct cardiomyopathy specific to diabetes, termed 'diabetic cardiomyopathy'. The natural history is characterized by a latent subclinical period, during which there is evidence of diastolic dysfunction and left ventricular hypertrophy, before overt clinical deterioration and systolic failure ensue. These clinical findings have been supported by a growing body of experimental data which support the notion that diabetes inflicts a direct insult to the myocardium, with cellular, structural and functional changes manifest as the diabetic myocardial phenotype. Several of these mechanisms appear to work in unison, forming complicated reciprocal pathways of disease. Reactive oxygen species and alterations in intracellular calcium homeostasis appear to play significant roles in many of these mechanisms. Determining the hierarchy of this cascade of disease will allow identification of the pathological trigger most responsible for disease. Translational research in this field is currently hindered by a lack of clinical studies and intervention trials specifically in patients with diabetic cardiomyopathy. Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients.

AB - Diabetic individuals have a significantly increased likelihood of developing cardiovascular disease. Whilst part of this association is explained by the presence of concomitant risk factors, large epidemiological studies have consistently reported diabetes as a strong risk factor for the development of heart failure after adjusting for such covariates. This has resulted in the notion that there is a distinct cardiomyopathy specific to diabetes, termed 'diabetic cardiomyopathy'. The natural history is characterized by a latent subclinical period, during which there is evidence of diastolic dysfunction and left ventricular hypertrophy, before overt clinical deterioration and systolic failure ensue. These clinical findings have been supported by a growing body of experimental data which support the notion that diabetes inflicts a direct insult to the myocardium, with cellular, structural and functional changes manifest as the diabetic myocardial phenotype. Several of these mechanisms appear to work in unison, forming complicated reciprocal pathways of disease. Reactive oxygen species and alterations in intracellular calcium homeostasis appear to play significant roles in many of these mechanisms. Determining the hierarchy of this cascade of disease will allow identification of the pathological trigger most responsible for disease. Translational research in this field is currently hindered by a lack of clinical studies and intervention trials specifically in patients with diabetic cardiomyopathy. Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients.

KW - cardiomyocyte

KW - cardiomyopathy

KW - diabetes

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=66449134228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449134228&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2008.10.016

DO - 10.1016/j.beem.2008.10.016

M3 - Review article

C2 - 19520308

AN - SCOPUS:66449134228

VL - 23

SP - 347

EP - 360

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 3

ER -